OPTIMIZING THE TREATMENT OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASE WITH LERCANIDIPINE

Abstract

Comorbidity of cardiovascular diseases reciprocally aggravates their course and induces the need to use safety and well-tolerated drugs. Pharmacological and pharmacokinetic properties of lercanidipine – the third-generation calcium channel blocker – are characterized by high lipophilicity and tissue selectivity. Clinical studies provide evidence of antihypertensive efficacy and safety of lercanidipine that is successfully used in patients with arterial hypertension and coronary heart disease.

Keywords

• сердечно-сосудистые заболевания
• антигипертензивное лечение
• блокаторы кальциевых каналов
• лерканидипин